Advanced Clinical Laboratory Solutions Calls for Increased Availability, Expanded Access to Toxicology Testing at Labs Nationwide

BROOKLYN, N.Y.–(BUSINESS WIRE)– With increased national focus on opioid abuse and deaths from drug
overdose annually claiming 47,055 lives,
Advanced
Clinical Laboratory Solutions, Inc. (ACLS), an independent
clinical laboratory specializing in clinical toxicology and
pharmacogenetics that provides convenient, high-quality testing services
and accurate, timely test results to patients, physicians and medical
centers in 20+ states, points to the critical need for individuals
nationwide to have greater access to toxicology testing at smaller
laboratory testing facilities. Improved scheduling opportunities, faster
turnaround of test results, accurate reporting and more competitive
pricing – the hallmarks of nimbler and more responsive labs – can make
the difference for millions of Americans potentially needing addiction
treatment.

“Laboratory drug testing is critical for supporting clinicians, but with
insurance costs on the rise, many of those suffering from addiction are
unable to get full coverage for lab testing,” says Dr. Leon Reyfman,
M.D., CEO, ACLS. “Given the persistent and evolving introduction of new
and highly dangerous drugs in communities, drug testing as a primary
prevention, diagnostic and monitoring tool can identify the presence or
absence of drugs of abuse or therapeutic agents in multiple settings.
Making lab testing more affordable and available across communities is
essential for preventing drug abuse – and saving lives – especially
among teens and young adults.”

Diane J. Savino, re-elected six times to represent the 23rd Senate
District in the New
York State Senate, in northern Staten
Island and parts of southern Brooklyn,
including Sunset
Park and Coney
Island, reinforces this need, saying, “Addiction to opioids and the
use of street drugs, such as the devastating rash of K2 overdoses in New
York City, pose serious community issues that impact public health and
social welfare. This national epidemic raises the importance of drug
testing, and shines a spotlight on the need for insurance coverage when
these tests are performed at smaller laboratory testing services
throughout the country.”

An effective approach to drug testing includes greater use of random
testing of urine, blood, saliva, hair, nails, sweat and breath when
those matrices match the intended assessment process. ACLS offers
medical research, quality and expedient testing that exceeds current
standards of clinical toxicology, providing clients with the highest
toxicology and clinical testing in the industry, including drug testing
of urine and oral fluids, and pharmacogenetics for personalized
prescribing.

Robert T. Hettenbach, recent chair, Advanced
Health Network IPA and president, PSCH,
emphasizes the role of ACLS working with state and federal government,
health plans, hospitals, providers, and most importantly patients to
create value and better outcomes for all.

“By initiating ongoing innovations for toxicology testing, ACLS will
implement more effective outreach, engagement, treatment, and
coordination with the health and mental health systems and social
supports,” says Hettenbach. “Accessible, reliable, and rapid testing
enables care-givers and clients to get the information necessary to
achieve highest quality and outcomes. With implementation of the Delivery
System Reform Incentive Payment (DSRIP) Program and other healthcare
reforms, the timing for ACLS innovations is ideal.”

About ACLS

ACLS is a provider of diagnostic laboratory testing, information and
services that enable physicians and other healthcare professionals to
make decisions to improve health. Clinical laboratory testing is an
essential element in the delivery of healthcare services. Physicians use
laboratory tests to assist in the detection, diagnosis, evaluation,
monitoring and treatment of diseases and other medical conditions. Visit https://www.aclsdiagnostics.com/.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160802005403/en/